Headlands Technologies’s BioCryst Pharmaceuticals BCRX Stock Holding History

Headlands Technologies’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$692K	Sell	72,652 -45,821	-39%	-$356K	0.08%	295
2025 Q4	$924K	Buy	118,473 +4,134	+4%	+$29.9K	0.08%	285
2025 Q3	$868K	Buy	114,339 +59,118	+107%	+$492K	0.07%	263
2025 Q2	$495K	Buy	55,221 +51,002	+1,209%	+$475K	0.06%	303
2025 Q1	$31.6K	Buy	+4,219	New	+$34K	﹤0.01%	787
2024 Q3	–	Sell	-16,750	Closed	-$104K	–	1195
2024 Q2	$104K	Buy	+16,750	New	+$92.4K	0.01%	636

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Headlands Technologies's BCRX Position: Q1 2026 in Review

Headlands Technologies reduced its BioCryst Pharmaceuticals (BCRX) stake by 39% in Q1 2026, selling an estimated $356K and leaving 72,652 shares worth $692K. The position accounts for 0.08% of the portfolio, ranked #295.

Headlands Technologies first reported a position in BCRX in Q2 2024 and has held it in 6 quarters since. The position peaked at $924K in Q4 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Headlands Technologies held 72,652 shares of BioCryst Pharmaceuticals worth $692K as of Q1 2026.
Headlands Technologies sold 45,821 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $356K.
BioCryst Pharmaceuticals made up 0.08% of Headlands Technologies's portfolio in Q1 2026, its #295 holding.
Headlands Technologies first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
Headlands Technologies's BioCryst Pharmaceuticals position peaked at $924K in Q4 2025.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.